DexCom - DXCM Stock Forecast, Price & News

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

DexCom Stock Down 1.7 %

DXCM opened at $88.24 on Friday. The company has a debt-to-equity ratio of 0.87, a current ratio of 4.72 and a quick ratio of 4.30. The company's 50-day moving average is $78.92 and its 200 day moving average is $94.89. DexCom has a fifty-two week low of $66.89 and a fifty-two week high of $164.86. The firm has a market capitalization of $34.64 billion, a P/E ratio of 183.84, a PEG ratio of 3.41 and a beta of 1.03.

DexCom (NASDAQ:DXCM - Get Rating) last announced its quarterly earnings data on Thursday, July 28th. The medical device company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.19 by ($0.02). The company had revenue of $696.20 million during the quarter, compared to the consensus estimate of $709.33 million. DexCom had a return on equity of 11.79% and a net margin of 7.47%. The business's revenue was up 17.0% on a year-over-year basis. During the same period in the prior year, the firm posted $0.19 EPS. Research analysts expect that DexCom will post 0.79 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently weighed in on DXCM. Citigroup decreased their price objective on shares of DexCom from $105.00 to $100.00 in a research report on Friday, July 29th. Robert W. Baird reduced their price target on shares of DexCom from $115.00 to $97.00 in a report on Friday, July 29th. Wells Fargo & Company reduced their price target on shares of DexCom from $144.00 to $102.00 in a report on Friday, July 29th. Piper Sandler reduced their price target on shares of DexCom from $120.00 to $110.00 and set an "overweight" rating for the company in a report on Friday, July 29th. Finally, Canaccord Genuity Group reduced their price target on shares of DexCom from $131.25 to $125.00 in a report on Friday, April 29th. Two research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to MarketBeat, DexCom currently has a consensus rating of "Moderate Buy" and an average price target of $115.23.

Insiders Place Their Bets

In other DexCom news, Director Steven Robert Pacelli sold 250 shares of DexCom stock in a transaction dated Tuesday, May 24th. The shares were sold at an average price of $296.33, for a total value of $74,082.50. Following the sale, the director now owns 35,175 shares of the company's stock, valued at $10,423,407.75. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other DexCom news, Director Steven Robert Pacelli sold 250 shares of DexCom stock in a transaction dated Tuesday, May 24th. The shares were sold at an average price of $296.33, for a total value of $74,082.50. Following the sale, the director now owns 35,175 shares of the company's stock, valued at $10,423,407.75. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Jereme M. Sylvain sold 600 shares of DexCom stock in a transaction dated Monday, June 6th. The stock was sold at an average price of $301.57, for a total transaction of $180,942.00. Following the completion of the transaction, the chief financial officer now owns 17,408 shares of the company's stock, valued at approximately $5,249,730.56. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 2,850 shares of company stock valued at $410,645. Company insiders own 0.41% of the company's stock.